# EDGAR Filing Document

**Accession Number:** 0001095981
**File Stem:** 0001193125-25-179175
**Filing Date:** 2025-8
**Character Count:** 2302
**Document Hash:** 103728fffb1f472868b31ec6a2da3957
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-179175.hdr.sgml**: 20250912

**ACCESSION NUMBER**: 0001193125-25-179175

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250812

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PLUS THERAPEUTICS, INC.
- **CENTRAL INDEX KEY:** 0001095981
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 330827593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756
- **BUSINESS PHONE:** 737.255.7194

**MAIL ADDRESS:**
- **STREET 1:** 4200 MARATHON BLVD.
- **STREET 2:** SUITE 200
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78756

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CYTORI THERAPEUTICS, INC.
- **DATE OF NAME CHANGE:** 20050712

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MACROPORE INC
- **DATE OF NAME CHANGE:** 20010320

August 12, 2025

**<u>VIA EDGAR</u>**

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

---

| | |
|:---|:---|
| **Re:** | **Plus Therapeutics, Inc.**  |

---

**Registration Statement on Form S-1 filed on August 12, 2025** 

**File No. 333-289526** 

**Request for Acceleration of Effective Date** 

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, Plus Therapeutics, Inc. hereby requests for acceleration of the effective date of the above-referenced registration statement, as amended, so that it becomes effective as of 5:30 p.m. Eastern Time on Thursday, August 14, 2025, or as soon thereafter as possible.

*[Signature Page to Follow]* 

------

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| **Plus Therapeutics, Inc.** | **Plus Therapeutics, Inc.** |
| By: | /s/ Andrew Sims |
| Name: Andrew Sims | Name: Andrew Sims |
| Title: Chief Financial Officer | Title: Chief Financial Officer |

---

cc: Aaron M. Schleicher, Sullivan & Worcester LLP

*[Signature Page to Acceleration Request]*